Amsterdam-based startup Onera Health has raised €30 million ($32 million) in a Series C funding round to further develop its home-based sleep diagnostic and monitoring technology. Onera provides a clinical-grade solution, offering end-to-end “polysomnography-as-a-service,” allowing healthcare professionals to conduct sleep studies directly in patients’ homes or labs.
The process involves shipping wireless sensors to the patient, who attaches them as instructed, and then returns the hardware to Onera for data processing.
The company has secured regulatory clearance from the FDA in the U.S. and plans to use the funding to expedite regulatory clearance for its second-generation polysomnography system in the U.S. and Europe. The funding round was co-led by EQT Life Sciences and Gimv, with participation from other investors.
Onera Health, a Netherlands-based startup specializing in sleep diagnostic and monitoring technology, has successfully raised €30 million ($32 million) in a Series C funding round. The company focuses on providing clinical-grade solutions, offering an end-to-end “polysomnography-as-a-service” that enables healthcare professionals to conduct sleep studies either in patients’ homes or in labs.
Onera’s process involves shipping wireless sensors directly to the patient, who then attaches them as instructed. The collected data is sent back to Onera for processing in its cloud platform, and a detailed report is generated for the clinician’s assessment.
The company has received regulatory clearance from the U.S. Food and Drug Administration (FDA). With a total funding of €55 million since its founding in 2017, Onera aims to expedite regulatory clearance for its second-generation polysomnography system in both the U.S. and Europe, where it currently serves the Benelux and DACH regions.
The Series C funding round was co-led by EQT Life Sciences and Gimv, with the participation of other investors. Onera plans to allocate the funds towards research and development, customer success initiatives, and geographic expansion to address the increasing demand for sleep disorder solutions.